Overview
Join Us for the Ten Year Special Planning Anniversary at DIA China 10th Annual Meeting
Every year at May, the DIA China Annual Meeting, which includes the whole chain of drug R&D and focuses on clinical and regulatory science, has become the most important opportunities to exchange ideas and practices, expand network and display products & services in China healthcare community.
The 10th DIA China Annual Meeting from May 22-25, 2018 will bring together more than 2000 pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments.
Special DIAmond Sessions will introduce global views into our perspective of the Chinese pharmaceutical ecosystem. Sessions will model the experience from the global DIA 2017 Annual Meeting in the US. As the largest multidisciplinary event in DIA Asia, other highlights will include 100+ exhibit booths and a new, unique hub for R&D and emerging companies to showcase themselves in “Innovation Hub.”
Professionals involved at all levels in the regulation, discovery, development, and life cycle management of health care products, will travel from China and around the world to witness transformational changes for China’s innovation and regulatory environment, to share the view points, knowledge, new technologic progress, and cross-cutting collaboration towards patient centric biopharma innovation in China.
Featured topics
- Special Forum at the Opening
- Regulatory Science
- CFDA Town Hall
- Innovative Breakthrough in Therapy (Oncology, Cardiac, etc.)
- Clinical Development (Operations, Site, GCP, etc.)
- Quantitative Science
- CMC & Generic Drugs
- Biologics & Biosimilar Development
- Medical Affairs
- Safety & Pharmacovigilance
- Patient Engagement
- Big Data Research and Artificial Intelligence in Healthcare
- Medical Devices, Companion Diagnostics, IVD
- Hot Topics and Late Breaker (Rare Diseases, CV Research Network, Investment & BD, Portfolio Management, Payer, etc.)
Program Committee
-
Pei HU • Director, Phase I Unit, Clinical Pharmacological Research Center
Peking Union Medical College, China -
Bin Xue • Director-General
China Center for Food and Drug International Exchange, CFDA, China -
Wendy Yan, MD, MBA • Senior Vice President, Head of Regulatory Affairs
BeiGene (Beijing) Co., Ltd., China -
Irene Deng • Vice President, Head of China Regulatory Affairs
AstraZeneca, China -
Jin Cui • Program Officer
China Center for Food and Drug International Exchange , China -
George LIU • Head of Early Development and Scientific Operation
Harbour Biomed, China -
Zhiqiang Ning • Vice President, Research & Clinical Development
Shenzhen Chipscreen Biosciences, Ltd., China -
Jessica Liu • Vice President, Head of International Business
TigerMed China, China -
Sunny Zhu • Chief Medical Officer, Infectious Diseases
Everest Medicines, China -
Hannah Chen, MD • Director, Asia Pacific Strategy Lead
BioResearch Quality & Compliance, Janssen, China -
Paul Dai, MD • Head of Clinical Operations
TDC, Asia, Takeda, China -
Reako Ren • Head of SMO Services
WuXi Apptec., China -
Connie DAI •
Harbour Biomed, China -
Hualong Sun • General manager
Meta Clinical Technical Co. Ltd, China -
Charles Yan • Vice President
Hengrui Data Science Center, China -
Melly Lin • Senior Regulatory Manager, CMC Policy,
Roche(China) Holding Ltd, China -
Joe Zhang • Former Head of Preclinical R&D
Simcere Pharmaceutical Group, China -
Xiangyang Zhu • CEO
Shanghai Huaota Biopharma Co., Ltd, China -
Li L Wang • Vice President, Medical
Eli Lilly, China -
Xiaoling Wang • Clinical Documentation
Clinical Science Operation, Sanofi R&D China, China -
Xue TANG • Drug Safety Unit Regional Head (DRH),
APAC Pfizer, China -
Dayao ZHAO, MD, PhD • Vice President and Lead, China Drug Development
Pfizer, China -
Jane Y. Cai, PhD • Former Managing Director
DIA China, China -
Tony Guo • Executive Director, Head of Biometrics China
BeiGene, China -
Tong Guo • Vice President and Head of Sales
Greater China IQVIA, China -
Amber Wang • Vice President, Regulatory Affairs & QA
SmithNephew, China -
Ruyi He, MD • Chief Scientist
Center for Drug Evaluation, CFDA, United States -
Jingsong WANG, MD • CEO
Harbour Biomed (HBM), China -
Shun Lu • Director, Shanghai Lung Cancer Center
Shanghai Jiaotong University, China -
Xianglin Zhang • President
Shenyang Pharmaceutical University, China -
Carol Zhu, MBA • Senior Vice President and Managing Director
DIA China, China -
Ron D. Fitzmartin, DIAFellow, PhD, MBA • Senior Advisor, Office of Strategic Programs, CDER
FDA, United States -
Murray M. Lumpkin, DIAFellow, MD, MSc • Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation, United States -
Kenneth A. Getz, DIAFellow, MBA • Director of Sponsored Research Programs and Associate Professor
Center For the Study of Drug Development, Tufts University School of Medicine, United States -
Sandra A. Milligan, DIAFellow, JD, MD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety
Merck Research Laboratories, United States -
Ling Su, DIAFellow, PhD • Past President, DIA Board of Directors; Professor
Shenyang Pharmaceutical University, China
Contact us
Registration?
Exhibition Sales and Services Questions?
Peng ZHENG
86 10 8221 2866*6007
Jianying CHENG 86 10 8221 2866*6008
Exhibits Managed by China Center for Food and Drug International Exchange (CCFDIE).